

Guselkumab (Tremfya®)

Guselkumab is a human immunoglobulin G1 λ monoclonal antibody that binds to the p19 subunit of interleukin-23 (IL-23) and blocks it from the IL-23 receptor.

Resources from Manufacturer

[Patient Medication Guide](#)
[Full Prescribing Information](#)
[Patient Support Program](#)
[Janssen Patient Assistance Program](#)
[J&J Patient Assistance Program](#)

FDA-Approved Indications and Dosing in Rheumatology

Guselkumab is indicated for:

- Adults with active psoriatic arthritis
- Adults with moderate-to-severe plaque psoriasis

Subcutaneous dosing:

Inject 100 mg under the skin at weeks 0, 4, and then every 8 weeks thereafter

Contraindications History of serious hypersensitivity to guselkumab or any of its excipients

Warnings and Precautions

1. Anaphylaxis or hypersensitivity reaction
2. Infections
3. Tuberculosis
4. Avoid live vaccines while on treatment

Adverse Reactions ($\geq 1\%$)

- Upper respiratory tract infection
- Headache
- Injection site reactions
- Arthralgia
- Diarrhea, gastroenteritis
- Tinea infections
- Herpes simplex infections

Medication Strength and Preparations

- Single-dose prefilled auto-injector (Tremfya One-Press patient-controlled injector): 100 mg/mL
- Single-dose prefilled syringe: 100 mg/mL

Medication Administration and Storage

- Store in original carton to protect from light
- Store in refrigerator at 2°C to 8°C [36°F to 46°F]—do not freeze
- Before injecting, allow injection to warm to room temperature for at least 30 minutes prior to administration
- Inject subcutaneously into front of thigh, lower abdomen (avoid injecting within 2 inches of navel), or back upper arm
- Do not administer into tender, bruised, red or hard skin
- Rotate injection sites (≥ 1 inch apart)
- Safe at room temperature (defined as up to 30°C [86°F]) one time only for up to 4 hours
- Does not contain natural rubber latex

Updated June 2024—ARP Practice Committee

DISCLAIMER: The information contained in this biologic reference guide is offered solely for purposes of providing health care professionals with a quick and initial reference. Before prescribing or administering any drug contained in this biologic reference guide, health professionals should read the manufacturer's complete prescribing information in order to be informed of the various clinical considerations to be taken into account. The American College of Rheumatology is providing this information as a benefit and service in furtherance of its educational mission. By providing this information, ACR is not endorsing or recommending any of the listed companies or any of their drugs or other products. The information contained in the biologic reference guides reflect the conclusions of the individual companies and not those of the ACR which specifically disclaims any responsibility or liability for the use of such information and/or for the performance of any of the drugs listed in this biologic reference guide.